Compagnie Lombard Odier SCmA Sells 13,260 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Compagnie Lombard Odier SCmA reduced its stake in IQVIA Holdings Inc. by 10.4%, selling 13,260 shares and retaining 114,332 shares worth approximately $18 million.
• Multiple analysts have upgraded IQVIA's stock ratings, with target prices raised to as high as $225, and the stock now holds a consensus rating of "Moderate Buy."
• IQVIA reported quarterly earnings of $2.81 per share, exceeding analyst expectations, and projected FY 2025 EPS guidance between 11.750-12.050.

Compagnie Lombard Odier SCmA trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 114,332 shares of the medical research company's stock after selling 13,260 shares during the quarter. Compagnie Lombard Odier SCmA owned 0.07% of IQVIA worth $18,018,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Oregon Pacific Wealth Management LLC boosted its position in shares of IQVIA by 26.5% in the second quarter. Oregon Pacific Wealth Management LLC now owns 3,109 shares of the medical research company's stock valued at $490,000 after acquiring an additional 652 shares during the period. Counterpoint Mutual Funds LLC acquired a new stake in IQVIA during the second quarter worth about $326,000. Leonard Rickey Investment Advisors P.L.L.C. grew its position in IQVIA by 12.4% during the second quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,505 shares of the medical research company's stock worth $237,000 after buying an additional 166 shares in the last quarter. Clear Harbor Asset Management LLC grew its position in IQVIA by 17.3% during the second quarter. Clear Harbor Asset Management LLC now owns 13,577 shares of the medical research company's stock worth $2,140,000 after buying an additional 2,007 shares in the last quarter. Finally, Park Avenue Securities LLC grew its position in IQVIA by 9.9% during the second quarter. Park Avenue Securities LLC now owns 5,963 shares of the medical research company's stock worth $940,000 after buying an additional 538 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and lifted their target price for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Barclays lifted their target price on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. Finally, Robert W. Baird lifted their price objective on IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $229.64.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Stock Performance

IQV stock opened at $187.72 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50 day moving average price of $185.35 and a 200 day moving average price of $167.16. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $245.20. The stock has a market capitalization of $31.91 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the previous year, the company posted $2.64 EPS. IQVIA's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.